- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Chordoma.
Displaying page 1 of 1.
EudraCT Number: 2004-001362-40 | Sponsor Protocol Number: CSTI571BIT15 | Start Date*: 2004-07-22 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: PHASE II STUDY OF IMATINIB MESYLATE IN CHORDOMA | |||||||||||||
Medical condition: Treatment of advanced or unresectable chordoma | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002766-31 | Sponsor Protocol Number: 1200.277 | Start Date*: 2018-11-23 | |||||||||||
Sponsor Name:UCL | |||||||||||||
Full Title: A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma | |||||||||||||
Medical condition: Chordoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004660-19 | Sponsor Protocol Number: NCT-2016-415 | Start Date*: 2017-11-22 | |||||||||||
Sponsor Name:University Hospital Heidelberg | |||||||||||||
Full Title: CDK4/6 inhibition in locally advanced/metastatic chordoma | |||||||||||||
Medical condition: Patients with locally advanced or metastatic chordoma refractory to treatment with tyrosine kinase inhibitors. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021755-34 | Sponsor Protocol Number: 2010-021755-34 | Start Date*: 2010-07-22 | |||||||||||||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||||||||||||
Full Title: Phase II study on imatinib in combination with RAD001 in advanced chordoma | |||||||||||||||||||||||
Medical condition: PDGFRB and mTOR (or S6 or 4BP1) positive advanced chordoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014456-29 | Sponsor Protocol Number: Cord01 | Start Date*: 2009-09-25 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: PHASE II STUDY OF LAPATINIB IN EGFR/HER2NEU POSITIVE ADVANCED CHORDOMA | |||||||||||||
Medical condition: Advanced chordoma EGFR/Her2Neu positive | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004045-16 | Sponsor Protocol Number: ET18-272 | Start Date*: 2019-03-14 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: REGOSTA – A randomized, placebo-controlled, double-blinded, multicentre study evaluating the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bo... | ||
Medical condition: Patients with bone sarcomas other than Ewing sarcoma or chondrosarcoma or chordoma, who have no residual disease after neoadjuvant chemotherapy, surgery and/or adjuvant chemotherapy. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002469-41 | Sponsor Protocol Number: EZH-202 | Start Date*: 2016-04-18 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Epizyme, Inc. | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Cohort 1: Rhabdoid tumors (malignant rhabdoid tumors, rhabdoid tumors of the kidney, atypical teratoid rhabdoid tumors, and selected tumors Cohort 2: Relapsed/refractory synovial sarcoma with SS18... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) FR (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002629-31 | Sponsor Protocol Number: ET19-144 | Start Date*: 2021-01-07 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: REGOMAIN – A randomized, placebo-controlled, double-blinded, multicentre, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients with high grade bone sarcoma... | ||
Medical condition: Patients with high grade bone sarcomas (HGBS) at diagnosis or first relapse and without complete remission after standard treatment | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002821-28 | Sponsor Protocol Number: ET20-128 | Start Date*: 2020-12-24 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma o... | ||
Medical condition: Metastatic or unresectable advanced rare sarcomas | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003806-18 | Sponsor Protocol Number: IC2014-16 | Start Date*: 2016-03-24 |
Sponsor Name:INSTITUT CURIE | ||
Full Title: IMPROVEMENT OF LOCAL CONTROL IN SKULL BASE AND SPINE CHORDOMAS TREATED BY SURGERY AND PROTONTHERAPY TARGETING HYPOXIC CELLS REVEALED BY POSITRON EMISSION TOMOGRAPHY NITROIMIDAZOLE ([18F]FAZA) PET/C... | ||
Medical condition: Chordomas of the skull base, spine and sacrum | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002468-18 | Sponsor Protocol Number: EZH-102 | Start Date*: 2016-02-19 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Epizyme, Inc. | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Atypical teratoid rhabdoid tumor (ATRT), Malignant rhabdoid tumor (MRT), Rhabdoid tumor of kidney (RTK), selected tumors with rhabdoid features. Epithelioid sarcoma, Epithelioid malignant peripher... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) DE (Completed) NL (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002260-14 | Sponsor Protocol Number: UC-0105/1612 | Start Date*: 2017-04-03 |
Sponsor Name:UNICANCER | ||
Full Title: Secured access to pembrolizumab for adult patients with selected rare cancer types. | ||
Medical condition: Patients with unresectable locally advanced or metastatic, rare soft tissue sarcoma, visceral sarcoma, or bone sarcoma, rare ovarian cancer, primary central nervous system lymphomas (PCNSL), rare t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004168-30 | Sponsor Protocol Number: STS001 | Start Date*: 2012-08-07 | |||||||||||
Sponsor Name:Hannover Medical School | |||||||||||||
Full Title: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma | |||||||||||||
Medical condition: Metastatic or advanced soft tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004750-15 | Sponsor Protocol Number: AIO-STS-0415 | Start Date*: 2017-10-06 | ||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||
Full Title: A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma. | ||||||||||||||||||
Medical condition: advanced or metastatic soft tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
